Global and China DNA Sequencing Industry Research Report, 2014-2017
  • Oct.2014
  • Hard Copy
  • USD $2,100
  • Pages:85
  • Single User License
    (PDF Unprintable)       
  • USD $1,900
  • Code: PQ015
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,000
  • Hard Copy + Single User License
  • USD $2,300
      

DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a broad range of fields, including medicine, biology, geology, and agriculture.

With the advancement of DNA sequencing technology and dramatic decline in sequencing costs, DNA sequencing is increasingly showing its market potential in noninvasive detection, disease diagnosis, and personalized treatment. In 2013, the market size of global DNA sequencing (including equipment and consumables, service and workflow, etc.) approximated USD4.6 billion, up around 26% from the previous year. It is projected that by 2017 this figure will reach USD10.096 billion, exceeding USD10 billion for the first time.

Ever since 1975, DNA sequencing technology has been through four generations, but the fourth-generation technology—Nanopore sequencing is still under development. Due to technologies and costs, the second-generation high-throughput sequencers are the mainstream sequencing platform around the world, with its total number occupying over 95% of next-generation DNA sequencers worldwide.

The upstream sectors of DNA sequencing industry are extremely robust, with the global market dominated by the second-generation DNA sequencing enterprises including Illumina, Thermo Fisher Scientific (through Life Technologies), Roche and the third-generation sequencing enterprises such as Pacific Biosciences. A review of these giants’ development history shows that mergers and acquisitions are the main driving forces behind the great market power. In February 2014, Thermo Fisher Scientific acquired Life Technologies for USD13.6 billion, making it the industry giant second only to Illumina.

In China, the upstream sectors of DNA sequencing industry are virtually monopolized by foreign giants. BGI is the leader in China’s DNA sequencing service, and its second-generation DNA sequencers top the global chart in number. However, two of its sequencers—HiSeq 2000 and Ion Proton were entirely from Illumina and Life Technologies. In March 2013, BGI acquired Complete Genomics, a sign that BGI formally ventured into the upstream sectors of DNA sequencing industry. In June 2014, BGI’s two products—BGISEQ-1000 and BGISEQ-100 became the first second-generation DNA sequencers registered in China.

It is expected, however, that within the next five years the weak position of Chinese enterprises in upstream sectors will remain unchanged except for the epic M&A.

?基因测序 英文_副本.png

Global and China DNA Sequencing Industry Research Report, 2014-2017 mainly focuses on the followings:
20120114.gifFeatures, cost, etc. of DNA sequencing technology;
20120114.gifMajor M&As, genetic database, market size and structure, etc. of global DNA sequencing industry;
20120114.gifDevelopment, industry policies, market structure and prospects, etc. of DNA sequencing industry in China;
20120114.gifOperation, DNA sequencing business, etc. of 12 enterprises at home and abroad.

1. Overview of DNA Sequencing Industry
1.1 Definition
1.2 Industry Chain
1.3 Application
1.4 Development History and Technical Features
1.5 Cost

2. Global DNA Sequencing Industry
2.1 Industry Chain Layout of Major Enterprises
2.2 Major M&As
2.3 Genetic Database
2.4 Sequencer
2.5 Market Size and Prospects

3. China DNA Sequencing Industry
3.1 Development
3.2 Policy Environment
3.3 Market Structure
3.3.1 Sequencer
3.3.2 Service
3.4 Prospects

4. Key Enterprises
4.1 Illumina
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 R&D and Investment
4.1.6 DNA Sequencing
4.1.7 Development Prospects
4.2 Thermo Fisher Scientific
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Operating Margin
4.2.5 R&D and Investment
4.2.6 DNA Sequencing
4.2.7 Development in China
4.2.8 Development Prospects
4.3 BGI
4.3.1 Profile
4.3.2 Operation
4.3.3 DNA Sequencing
4.4 Roche
4.4.1 Profile
4.4.2 DNA Sequencing
4.5 Qiagen
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 R&D
4.5.5 DNA Sequencing
4.6 Pacific Biosciences
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 R&D
4.6.5 DNA Sequencing
4.7 Sequenom
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Operating Margin
4.7.5 R&D
4.7.6 DNA Sequencing
4.8 DAAN Gene
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 Gross Margin
4.8.5 R&D
4.8.6 DNA Sequencing
4.8.7 Development Prospects
4.9 Agilent Technologies
4.9.1 Profile
4.9.2 Operation
4.9.3 Revenue Structure
4.9.4 R&D
4.9.5 DNA Sequencing
4.10 Berry Genomics
4.10.1 Profile
4.10.2 DNA Sequencing
4.11 Hunan China Sun Pharmaceutical Machinery 
4.11.1 Profile
4.11.2 DNA Sequencing
4.12 Jilin Zixin Pharmaceutical Industrial
4.12.1 Profile
4.12.2 Operation
4.12.3 DNA Sequencing
DNA Sequencing Industry Chain
DNA Sequencing Technology Application by Field
Features of DNA Sequencing Technology and its Advantage and Disadvantage by Generation
Trend in Sequencing Cost per Genome, 2001-2014
Trend in Sequencing Cost per Megabase, 2001-2014
Industry Chain Distribution of Major Global DNA Sequencing Enterprises
Major M&As in Global DNA Sequencing Industry, 2007-2014
Trend in The DDBJ Nucleotide Sequence Database, 2002-2014
Trend in The DDBJ Nucleotide Sequence Database Structure, 2002-2014
Top 30 DDBJ Organisms by Number of Nucleotides as of Mar. 2014
Next-generation DNA Sequencing Data of GenBank, 2008-2014
Worldwide Top 30 Countries or Regions with Next-generation DNA Sequencer by Number of Centers as of Sept. 2014 
Global Next-Generation DNA Sequencer Distribution by Center as of Sept. 2014 
Global Next-Generation DNA Sequencer Market Structure by Product as of Sept. 2014
Global Next-Generation DNA Sequencing Market Structure by Enterprise as of Sept. 2014
Global Next-Generation DNA Sequencing Market Structure by Number of Generation as of Sept. 2014
Global Next-Generation DNA Sequencer Distribution by Region as of Sept. 2014 
Worldwide Top 30 Countries or Regions by Number of Next-Generation DNA Sequencers as of Sept. 2014
Next-Generation DNA Sequencer Market Structure of Global Genome Centers by Product as of Sept. 2014 
Top 10 Global Genome Centers by Number of Next-Generation DNA Sequencers as of Sept. 2014
Global DNA Sequencing Market Size and YoY Growth, 2009-2017E
Global DNA Sequencing Market Structure by Type, 2013
Global DNA Sequencing Market Structure, 2017E 
Global DNA Sequencing Target Market Potential
Policies on China DNA Sequencing industry, 2012-2014
China Next-generation DNA Sequencer Proportion in Global Market as of Sept. 2014
Revenue and Net Income of Illumina, 2007-2014
Revenue Structure of Illumina by Business, 2007-2013
Revenue Breakdown of Illumina by Region, 2007-2013
Gross Margin Trends of Illumina, 2007-2014
R&D Costs and % of Total Revenue of Illumina, 2007-2014
Illumina’s M&A History, 2007-2014
Illumina’s DNA Sequencers and Consumables (by Type) and Their Application
Revenue and Net Income of Illumina, 2014-2017E
Revenue and Net Income of Thermo Fisher Scientific, 2009-2014
Revenue Breakdown of Thermo Fisher Scientific by Business, 2009-2014
Revenue Breakdown of Thermo Fisher Scientific by Region, 2010-2013
Operating Margin of Thermo Fisher Scientific by Business, 2009-2014
R&D Costs and % of Total Revenue of Thermo Fisher Scientific, 2009-2014
Revenue and YoY Growth of Life Technologies, 2009-2013
Revenue and YoY Growth of Thermo Fisher Scientific in China, 2009-2013
Revenue and Net Income of Thermo Fisher Scientific, 2014-2017E
Revenue and YoY Growth of BGI, 2007-2013
Events of BGI’s DNA Sequencing Industry Layout, 1999-2014
Roche’s Revenue from Molecular Diagnosis and % of Total Revenue, 2009-2014
Roche’s Newly-released DNA Sequencing Products, 2012-2013
Revenue and Net Income of Qiagen, 2009-2014
Revenue Breakdown of Qiagen by Business, 2009-2014
Revenue Structure of Qiagen by Application, 2011-2014
Revenue Breakdown of Qiagen by Region, 2009-2013
R&D Costs and % of Total Revenue of Qiagen, 2009-2014
Revenue and Net Income of Pacific Biosciences, 2009-2014
Revenue Breakdown of Pacific Biosciences by Region, 2009-2013
R&D Costs and % of Total Revenue of Pacific Biosciences, 2009-2014
Pacific Biosciences’ Revenue from DNA Sequencing by Product, 2011-2014
Revenue and Net Income of Sequenom, 2009-2014
Revenue Breakdown of Sequenom by Segment, 2009-2014
Revenue Breakdown of Sequenom by Region, 2009-2013
Operating Margin of Sequenom by Segment, 2009-2014
R&D Costs and % of Total Revenue of Sequenom, 2009-2014
Sequenom’s Revenue from Gene Analysis by Segment, 2010-2013
Revenue and Net Income of DAAN Gene, 2009-2014
Revenue Breakdown of DAAN Gene by Business, 2009-2014
Revenue Breakdown of DAAN Gene by Region, 2009-2014
Gross Margin of DAAN Gene by Business, 2009-2014
R&D Costs and % of Total Revenue of DAAN Gene, 2009-2014
Revenue and Net Income of Agilent Technologies, FY2009-FY2014
Revenue Breakdown of Agilent Technologies by Business, FY2011-FY2014
Revenue Breakdown of Agilent Technologies by Region, FY2011-FY2013
R&D Costs and % of Total Revenue of Agilent Technologies, 2009-2014
Revenue and Net Income of DAAN Gene, 2014-2017E  
Major Events of Berry Genomics, 2010-2014
DNA Sequencing Products of Berry Genomics
Revenue and Net Income of Hunan Honghao Gene, 2012-2014
Hunan Honghao Gene‘s Medical Devices Registered Based on Gene Chip, 2012-2014
Revenue and Net Income of Jilin Zixin Pharmaceutical Industrial, 2009-2014
Development History of DNA Sequencing of Jilin Zixin Pharmaceutical Industrial, 2010-2014

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

Global and China Industrial Enzyme Industry Report, 2014-2017

In recent years, the global industrial enzyme preparation market size increased year by year, registering a CAGR of 5%, approximating USD4.2178 billion in 2014. At present, the global industrial enzym...

China Blood Product Industry Report, 2015-2018

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Human Vaccine Industry Report, 2015-2018

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to ...

2005- www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号